Search
WL-1002
go.drugbank.com/drugs/DB05346ExperimentalWL-1002 is developed by Winston Laboratories which is a topical cream formulation of 075% zucapaicin (also known as civamide), for the treatment of pain due to osteoarthritis.
Ciglitazone
go.drugbank.com/drugs/DB09201ExperimentalDeveloped by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class. … Several analogues were later developed, some of which—such as pioglitazone and troglitazone—made it to the market.
PYM50018
go.drugbank.com/drugs/DB05126ExperimentalWhen administered orally to a transgenic pre-clinical model of ALS, PYM50018 delays the loss of muscle strength and extends survival time. … It is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease).
Solithromycin
go.drugbank.com/drugs/DB09308InvestigationalSolithromycin is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired pneumonia (CAP) and other infections.
1,4-Dithiothreitol
go.drugbank.com/drugs/DB04447ExperimentalA reagent commonly used in biochemical studies as a protective agent to prevent the oxidation of SH (thiol) groups and for reducing disulphides to dithiols. [PubChem]
Neuropeptide Y
go.drugbank.com/drugs/DB11788ApprovedInvestigationalWithdrawnNeuropeptide Y is under investigation for the basic science of Type 2 Diabetes Mellitus.
Carlumab
go.drugbank.com/drugs/DB12718ApprovedWithdrawnCarlumab has been used in trials studying the treatment of Cancer and Prostate Cancer.
PI-0824
go.drugbank.com/drugs/DB05516InvestigationalThe goal of this therapy is to reduce the production of antibodies that cause PV blisters by acting only on the disease causing components of the immune system. … People with PV produce antibodies that attack the cells of the skin, resulting in blisters which, if left untreated, can lead to devastating infections and discomfort.
AGS-004
go.drugbank.com/drugs/DB05742InvestigationalNon-personalized HIV immunotherapies are unable to raise cytotoxic T lymphocytes against HIV antigens, fail to induce T cell memory, and, most importantly, do not provide antiviral protection against the … AGS-004 is a personalized RNA-loaded dendritic cellbased immunotherapy that is designed to stimulate the patient’s immune system to target and destroy the patient’s own unique viral burden.
Atuliflapon
go.drugbank.com/drugs/DB19029InvestigationalAtuliflapon is under investigation in clinical trial NCT05251259 (Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-severe Uncontrolled Asthma).